Skip to main content

Table 1 Patient characteristics

From: Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death

Patient sample

ALL5

ALL6

ALL10

ALL12

ALL16

ALL17

ALL18

ALL19

ALL20

ALL 21

Age (years.months)

14.5

5.0

15.6

3.4

2.8

3.2

6.5

7.5

7.4

11.7

Sex

Female

Female

Female

Female

Male

Male

Male

Male

Male

Male

Sample from relapse

No

Yes

No

No

No

No

No

No

No

No

Immunophenotype

Common-B

Common-B

Common-B

Pre-B

Pre-B

Pre-B

Pre-B

Pre-B

Pre-B

Pre-B

Cytogenetics

t(9;22)

Normal karyotype

t(12;21)t(5;17)

t(12;21)(p13;q22)

47 ~ 48,XY,+X,i(21)(q10),+ i(21)(q10),[cp9]/46,XY[1]

46 XY, - 21c

t(12,21)

44, X,-Y,t(4;14) (q25;q32

46,XY,t(1;19)(q(23;p13)[2]/46,XY[23]

t(12;21)(p13;q22)

Residual disease at day 15

42 × 10-2

Not performed

30 × 10-2

1.1 × 10-2

3.2 × 10-3

8.9 × 10-3

8 × 10-3

No MRD

5 x 10-3

No MRD

Residual disease at day 29

27 × 10-2

No MRD

7.3 × 10-3

3 × 10-4

No MRD

9 × 10-4

5 × 10-4

No MRD

No MRD

No MRD

  1. MRD: minimal residual disease.